Sexual HealthTier 3 β€” Animal + early human data

Melanotan II

MT-II Β· MTII

Non-selective melanocortin agonist with potent tanning (melanogenesis), libido-enhancing, and appetite-suppressing effects. Not FDA approved β€” significant side effect profile.

πŸ’‰ SC injection / Intranasal🧊 Lyophilised: refrigerate; reconstituted: refrigerate, use within 30 days

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’

Mechanism of Action

Non-selective MC1R, MC3R, MC4R, MC5R agonist. MC1R activation drives melanin production (tanning), MC3R/MC4R activation increases sexual arousal and suppresses appetite.

Clinical Applications

  • βœ“Tanning without UV exposure
  • βœ“Sexual dysfunction and low libido
  • βœ“Appetite suppression (off-label)

Dosing Protocol

Recommended Dosing

SC injection. 0.5–1 mg, starting at 0.1 mg to assess tolerance. Use sparingly β€” nasal sprays widely available but unregulated. Not recommended for routine clinical use.

Safety & Contraindications

Possible Side Effects

  • ⚠Nausea and vomiting (frequent)
  • ⚠Facial flushing
  • ⚠Involuntary erections
  • ⚠Darkening of pre-existing moles (monitor for change)
  • ⚠Fatigue
  • ⚠Hypertension

Contraindications

  • βœ•History of melanoma or abnormal moles
  • βœ•Cardiovascular disease
  • βœ•Pregnancy
  • βœ•Hypertension

Combinations & Synergies

πŸ”— PT-141avoid (same receptor β€” additive side effects without benefit)